Abraxis BioScience's Abraxane meets key treatment goal in lung cancer study
LOS ANGELES (AP) -- Abraxis BioScience Inc. said Wednesday its drug Abraxane met key treatment goals in a late-stage lung cancer study.
The company said Abraxane with Taxol, in combination with chemotherapy, improved the overall response rate of patients in the 1,052 patient study. The study focused on patients receiving initial treatment for lung cancer and compared the Abraxane combination with patients only receiving Taxol and another chemotherapy, carboplatin.
Abraxane is already approved as a breast cancer treatment. The company expects to ask for FDA approval as a lung cancer treatment in 2011.
Shares of Abraxis jumped $12.77, or 32.1 percent, to $52.62 in morning trading. The stock has traded between $24.52 and $57.60 over the last 52 weeks
4 comments:
I am interested the procedure.. keep us posted.
I am, as well.
I believe one of our lung cancer support group members here in Columbia, SC is one of two particpating in the trial here in our area.
"The Phase 3 trial completed enrollment of 1,052 patients in July 2009 at 102 sites globally and was led by principal investigator Mark Socinski, M.D., at the University of North Carolina Lineberger Comprehensive Cancer Center."
More information can be found at: http://phx.corporate-ir.net/phoenix.zhtml?c=217234&p=irol-newsArticle&ID=1403220&highlight=
I am visiting this site first time..Really great articles... very informative for my knowledge..Thank you
Mesothelioma Blog
Good that there is a relief and hope and a better mode of cure for the breast cancer patients.Any kind of cancer is painful and there is a lot of need for the medical fraternity to extend more and more help to the patients of the same.
Post a Comment